23.80

3.30% 0.76

After Hours: 23.80

Dianthus Therapeutics Inc (DNTH)

Overview News Price History Financials Discussions Forecast

Dianthus Therapeutics Inc stock is traded at $23.80, with a volume of 381.09K. It is up +3.30% in the last 24 hours and up +14.59% over the past month. Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Previous Close:

$23.04

Open:

$22.79

24h Volume:

381.09K

Relative Volume:

1.49

Market Cap:

$704.41M

Revenue:

$4.12M

Net Income/Loss:

$-56.68M

P/E Ratio:

EPS:

Net Cash Flow:

$-51.44M

1W Performance:

-0.04%

1M Performance:

+14.59%

6M Performance:

-7.97%

1Y Performance:

+213.16%

1-Day Range:

$22.35

$24.21

1-Week Range:

$22.35

$24.65

52-Week Range:

$7.75

$33.77

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name

Dianthus Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

857-201-2700

Address

300 TECHNOLOGY SQUARE, CAMBRIDGE

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

DNTH's Discussions on Twitter

Compare DNTH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNTH Dianthus Therapeutics Inc	23.80	704.41M	4.12M	-56.68M	-51.44M	-5.5429
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-26-24	Initiated	Robert W. Baird	Outperform
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy
Feb-15-24	Initiated	Stifel	Buy
Dec-26-23	Initiated	Jefferies	Buy
Nov-22-23	Initiated	Wedbush	Outperform
Oct-30-23	Initiated	Guggenheim	Buy
Sep-28-23	Initiated	Raymond James	Outperform
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-06-22	Upgrade	Goldman	Neutral → Buy
Aug-20-21	Resumed	Goldman	Neutral
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-21	Reiterated	B. Riley Securities	Buy
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight
Jun-15-21	Initiated	BTIG Research	Buy
May-18-21	Initiated	B. Riley Securities	Buy
Jan-07-21	Initiated	Mizuho	Buy
Jun-08-20	Upgrade	Goldman	Neutral → Buy
Mar-25-19	Downgrade	Goldman	Buy → Neutral
Mar-15-19	Initiated	Raymond James	Outperform

View All

Dianthus Therapeutics Inc Stock (DNTH) Latest News

Dec 20, 2024

Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics - Benzinga

Dec 20, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at TD Cowen - MarketBeat

Dec 20, 2024

Dec 19, 2024

Wellington Management Group LLP Invests $1.47 Million in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Dec 19, 2024

Dec 15, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Raymond James - Defense World

Dec 15, 2024

Dec 14, 2024

Raymond James Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Moderate Buy - MarketBeat

Dec 14, 2024

Charles Schwab Investment Management Inc. Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Dec 14, 2024

Charles Schwab Investment Management Inc. Boosts Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Dec 14, 2024

Dec 08, 2024

Point72 Asset Management L.P. Buys 263,500 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Dec 08, 2024

Dec 07, 2024

Janus Henderson Group PLC Acquires 273,670 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Dec 07, 2024

30,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Walleye Capital LLC - MarketBeat

Dec 07, 2024

Dec 04, 2024

HighVista Strategies LLC Purchases New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Dec 04, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asia Singapore Pte. Ltd. - MarketBeat

Dec 04, 2024

Dec 03, 2024

Avidity Partners Management LP Increases Stake in Dianthus Thera - GuruFocus.com

Dec 03, 2024

Dec 02, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Dec 02, 2024

Quest Partners LLC Has $31,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Dec 02, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages - Defense World

Dec 02, 2024

Nov 30, 2024

Braidwell LP Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Nov 30, 2024

Nov 29, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Vestal Point Capital LP - MarketBeat

Nov 29, 2024

Nov 27, 2024

Great Point Partners LLC Lowers Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Nov 27, 2024

Nov 23, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5.1%What's Next? - MarketBeat

Nov 23, 2024

Nov 20, 2024